Contrave Bound For Korea As Orexigen Links With Local Firm

After settling a long dispute with its marketing partner for the US market, Orexigen Therapeutics has inked an agreement with Kwang Dong Pharm to distribute its obesity drug in South Korea, where demand is growing amid an increasing number of hypertension, hyperlipidemia and diabetes patients.

SEOUL - Orexigen Therapeutics Inc. has partnered with Kwang Dong Pharmaceutical Co. Ltd. to distribute its obesity drug Contrave (naltrexone/bupropion) in South Korea as it seeks to expand the drug’s global presence following the recent settlement of a dispute with its partner for the US market.

Under the terms of the agreement, the South Korean pharma firm will be responsible for seeking regulatory approval and for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia